| Literature DB >> 33980142 |
Sima Patel1, Amay Parikh2, Okorie Nduka Okorie2.
Abstract
BACKGROUND: Subarachnoid hemorrhage accounts for more than 30,000 cases of stroke annually in North America and encompasses a 4.4% mortality rate. Since a vast number of subarachnoid hemorrhage cases present in a younger population and can range from benign to severe, an accurate diagnosis is imperative to avoid premature morbidity and mortality. Here, we present a straightforward approach to evaluating, risk stratifying, and managing subarachnoid hemorrhages in the emergency department for the emergency medicine physician. DISCUSSION: The diversities of symptom presentation should be considered before proceeding with diagnostic modalities for subarachnoid hemorrhage. Once a subarachnoid hemorrhage is suspected, a computed tomography of the head with the assistance of the Ottawa subarachnoid hemorrhage rule should be utilized as an initial diagnostic measure. If further investigation is needed, a CT angiography of the head or a lumbar puncture can be considered keeping risks and limitations in mind. Initiating timely treatment is essential following diagnosis to help mitigate future complications. Risk tools can be used to assess the complications for which the patient is at greatest.Entities:
Keywords: Aneurysmal subarachnoid hemorrhage; Emergency department; Hunt and Hess; Modified Fischer; Neurologic injury; Non-aneurysmal subarachnoid hemorrhages; Subarachnoid hemorrhage
Year: 2021 PMID: 33980142 PMCID: PMC8117305 DOI: 10.1186/s12245-021-00353-w
Source DB: PubMed Journal: Int J Emerg Med ISSN: 1865-1372
Differential diagnoses for sudden onset headache [2, 4]
• Subarachnoid hemorrhage (aneurysmal, arteriovenous malformation, traumatic, perimesencephalic, unknown etiology) • Meningitis/encephalitis • Temporal arteritis/complicated migraine • Cluster headache • Reversible cerebral vasoconstriction syndrome • Acute narrow-angle closure glaucoma • Hypertensive emergencies • Acute strokes: hemorrhagic or ischemic • Carbon monoxide poisoning • Idiopathic intracranial hypertension (pseudotumor cerebri) • Spontaneous intracranial hypotension • Cerebral venous and dural sinus thrombosis • Mass lesions • Cervico-cranial artery dissections • Pituitary apoplexy |
Physical exam and history predictors of SAH
| Finding | Positive LR | Negative LR |
|---|---|---|
| Exam neck stiffness | 6.59 | 0.78 |
| Subjective neck stiffness | 4.12 | 0.73 |
| Lethargy | 2.19 | 0.74 |
| Vomiting | 1.92 | 0.52 |
| Similar headache in past | 1.90 | 0.90 |
| Onset of headache 1–5 min | 1.79 | 0.88 |
| “Worst headache of life” | 1.25 | 0.24 |
| Nausea | 1.15 | 0.74 |
| Onset of headache < 1 h | 1.13 | 0.06 |
| Photophobia | 1.07 | 1.05 |
| Diplopia | 0.96 | 1.00 |
| Onset of headache < 1 min | 0.91 | 1.11 |
| Family history of cerebral aneurysm | 0.22 | 1.07 |
| Absence of “worst headache of life” | -- | 0.36 |
LR Likelihood ratio
Fig. 1Subarachnoid hemorrhage on CT head
Ottawa Subarachnoid Hemorrhage rule [11]
| For alert patients > 15 years of age with new severe non-traumatic headache reaching maximum intensity within 1 h | |
| Not for patients with new neurologic deficits, previous aneurysms, SAH, brain tumors, or history of similar headaches (≥ 3 episodes over ≥ 6 months) | |
| Investigate further if ≥ 1 finding is present | |
| 1. Symptoms of neck pain or stiffness | |
| 2. Age ≥ 40 years old | |
| 3. Witnessed loss of consciousness | |
| 4. Onset during exertion | |
| 5. Thunderclap headache (peak intensity immediately) | |
| 6. Limited neck flexion on exam |
World Federation of Neurologic Surgeons (WFNS) Scale [26]
| Grade | Glasgow Coma Scale | Motor deficit |
|---|---|---|
| 1 | 15 | Absent |
| 2 | 13–14 | Absent |
| 3 | 13–14 | Present |
| 4 | 7–12 | Present or absent |
| 5 | 3–6 | Present or absent |
Hunt and Hess Classification [27, 28]
| Grades | Description | Mortality |
|---|---|---|
| 1 | Asymptomatic or minimal headache and slight nuchal rigidity | 3% |
| 2 | Moderate or severe headache, nuchal rigidity, no neurologic deficit other than cranial nerve palsy | 3% |
| 3 | Drowsiness, confusion, or mild focal deficit | 9% |
| 4 | Stupor, moderate to severe hemiparesis, possibly early decerebrate rigidity, and vegetative disturbance | 24% |
| 5 | Deep coma, decerebrate posturing, moribund appearance | 71% |
Modified Fisher Scale [29]
| Grade | Criteria on CT head | Incidence of Symptomatic Vasospasm |
|---|---|---|
| 0 | No SAH; no IVH | 0% |
| 1 | Focal or diffuse, thin SAH; no IVH | 24% |
| 2 | Thin, focal, or diffuse SAH; IVH | 33% |
| 3 | Thick, focal, or diffuse SAH; no IVH | 33% |
| 4 | Thick, focal, or diffuse SAH; IVH | 40% |
CT Computed tomography, SAH Subarachnoid hemorrhage, IVH Intraventricular hemorrhage
Medical complications of SAH
• Rebleeding • Vasospasm • Hyponatremia • Cerebral salt wasting • Seizures • Hydrocephalus • Herniation • Coma • Cardiogenic shock • Neurogenic stress cardiomyopathy |
Anticoagulation reversal agents
| Target agent | Reversal agent | Reversal agent mechanism of action | Dosing |
|---|---|---|---|
| Vitamin K antagonists | 3 factor or 4 factor prothrombin complex (PCC) | Replacing factors II, IX, X, and VII (4-factor PCC); protein C, S, and Z in other products | 25–50 U/kg intravenous |
| Factor Xa inhibitors, heparin, low-molecular weight heparin (LMWH), and fondaparinux | Andexanet alfa | Recombinant variant of human factor Xa that competes with native factor Xa for binding of rivaroxaban, apixaban, and edoxaban, and the heparin-, low-molecular weight heparin-, and fondaparinux-antithrombin complex | 400 mg intravenous bolus followed by intravenous infusion of 480 mg over 2 h for reversal of apixaban or rivaroxaban if > 7 h previously 800 mg followed by an infusion of 960 mg over 2 h for those taking rivaroxaban or rivaroxaban if ≤ 7 h previously or edoxaban |
| Dabigatran | Idarucizumab | Noncompetitive, specific, and direct binding of dabigatran | 5 g intravenous bolus |
| Antiplatelets | Platelets or desmopressin | Desmopressin increases release of von Willebrand factor in platelets thus increasing factor VIII availability for clotting | 0.4 mcg/kg Uremia, 0.3 mcg/kg |
g Grams, mcg Micrograms, kg Kilogram, mg Milligram, h Hour, U Units
Fig. 2Subarachnoid hemorrhage management algorithm